This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teng, R.
Right arrow Articles by Liston, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teng, R.
Right arrow Articles by Liston, T. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Mar 1996, 561-566, Vol 40, No. 3
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys

R Teng, D Girard, TD Gootz, G Foulds and TE Liston
Central Research Division, Pfizer Inc., Groton, Connecticut 06340, USA.

The pharmacokinetics of trovafloxacin [CP-99,219; 7-(3- azabicyclo[3.1.0]hexyl)-naphthyridone] were studied in rats, dogs, and monkeys following oral and intravenous administration. After intravenous dosing, the systemic clearances of trovafloxacin in rats, dogs, and monkeys were 12.5, 11.1, and 7.2 ml/min/kg of body weight, respectively, and the respective volumes of distribution were 0.9, 1.7, and 4.3 liters/kg, with corresponding elimination half-lives of 0.7, 1.8, and 7.0 h. After the administration of oral doses of 50, 20, and 20 mg/kg to rats, dogs, and monkeys serum trovafloxacin concentrations reached a maximum at 0.6, 2.3, and 2.3 h, respectively, with respective maximum concentrations of trovafloxacin in serum of 11.5, 3.5, and 5.2 micrograms/ml; the corresponding elimination half-lives were 2.2, 2.5, and 7.5 h. The oral bioavailability of trovafloxacin was 68, 58, and 85% in rats, dogs, and monkeys, respectively. The binding of trovafloxacin to serum proteins was concentration independent, averaging 92, 75, and 66% for rats, dogs, and monkeys, respectively. Trovafloxacin penetrated well into tissues in dogs. The urinary recoveries of unchanged drug were less than 5% in dogs and monkeys, with or without incubation with alkali or Glusulase (beta-glucuronidase and sulfatase). In rats, 99.8% of the orally administered radioactivity was recovered in feces, while 20.6, 3.4, and 67.1% of the radioactive dose in bile duct-cannulated rats were recovered in feces, urine, and bile, respectively. These results suggest that the elimination of trovafloxacin from rats, and possibly from dogs and monkeys, is primarily through biliary excretion.


This article has been cited by other articles:

  • Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., Roth, R. A. (2007). Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-Alpha. Toxicol Sci 100: 259-266 [Abstract] [Full Text]  
  • Olsen, K. M., Gentry-Nielsen, M., Yue, M., Snitily, M. U., Preheim, L. C. (2006). Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia. Antimicrob. Agents Chemother. 50: 210-219 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Peytavin, G., Isturiz, R., Moine, P., Rieux, V., Cherbuliez, C., Pechere, J. C., Fantin, B., Kohler, T. (2004). Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 48: 765-773 [Abstract] [Full Text]  
  • Join-Lambert, O. F., Michéa-Hamzehpour, M., Köhler, T., Chau, F., Faurisson, F., Dautrey, S., Vissuzaine, C., Carbon, C., Pechère, J.-C. (2001). Differential Selection of Multidrug Efflux Mutants by Trovafloxacin and Ciprofloxacin in an Experimental Model of Pseudomonas aeruginosa Acute Pneumonia in Rats. Antimicrob. Agents Chemother. 45: 571-576 [Abstract] [Full Text]  
  • Bradley, J. S., Kearns, G. L., Reed, M. D., Capparelli, E. V., Vincent, J., The Pediatric Pharmacology Research Unit Network, (2000). Pharmacokinetics of a Fluoronaphthyridone, Trovafloxacin (CP 99,219), in Infants and Children following Administration of a Single Intravenous Dose of Alatrofloxacin. Antimicrob. Agents Chemother. 44: 1195-1199 [Abstract] [Full Text]  
  • Ng, W., Lutsar, I., Wubbel, L., Ghaffar, F., Jafri, H., McCracken, G. H., Friedland, I. R. (1999). Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. J Antimicrob Chemother 43: 811-816 [Abstract] [Full Text]  
  • Entenza, J. M., Vouillamoz, J., Glauser, M. P., Moreillon, P. (1999). Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis. Antimicrob. Agents Chemother. 43: 77-84 [Abstract] [Full Text]  
  • Bédos, J.-P., Rieux, V., Bauchet, J., Muffat-Joly, M., Carbon, C., Azoulay-Dupuis, E. (1998). Efficacy of Trovafloxacin against Penicillin-Susceptible and Multiresistant Strains of Streptococcus pneumoniae in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 42: 862-867 [Abstract] [Full Text]  
  • Montgomerie, J. Z., Schick, D. G. (1998). Treatment of Enterococcal Pyelonephritis with Trovafloxacin and Rifampin: In Vitro-In Vivo Contrast. Antimicrob. Agents Chemother. 42: 188-189 [Abstract] [Full Text]  
  • Dalvie, D. K., Khosla, N., Vincent, J. (1997). Excretion and Metabolism of Trovafloxacin in Humans. Drug Metab. Dispos. 25: 423-427 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»